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Hepatocellular carcinoma is the most common primary malignancy of the liver in adults. It is also the ﬁfth most common solid
cancerworldwideandthethirdleadingcauseofcancer-relateddeath.Recentresearchsupportsthatlivercancerisadiseaseofadult
stem cells. From the models of experimental hepatocarcinogenesis, there may be at least three distinct cell lineages with progenitor
properties susceptible to neoplastic transformation. Identiﬁcation of speciﬁc cell surface markers for each of the liver cell types,
production of corresponding monoclonal antibodies and cell sorting techniques have together revolutionized the characteristics
of normal stem cells. In hepatocarcinogenesis, multiple signaling transduction pathways, important for stem cell proliferation and
diﬀerentiations, are deregulated. Strategies are being developed to identify and characterize the liver cancer stem cells. Targeting
liver cancer stem cells may bring hope to curing hepatocellular carcinoma.
1.Introduction
Hepatocellular carcinoma (HCC) is the most common
primary malignancy of the liver in adults. It is also the
ﬁfth most common solid cancer worldwide and the third
leading cause of cancer related death [1, 2]. Moreover, HCC
incidence and death rate are rising in the United States and
demonstrate the highest annual percent increase of the top
15 cancers by incidence [3]. The worldwide incidence of
HCC varies according to the prevalence of hepatitis B (HBV)
and hepatitis C (HCV) infection and the age-standardized
incidence rates vary from 4.9 per 100,000 population in
North America to 80 per 100,000 population in China [4].
It is worth noting that chronic HCV infection is the leading
cause of HCC in Europe, Japan, and the United States
whereas HBV infection is the leading cause in the majority
of Asian and African countries [2].
Recent research supports that cancer is a disease of
adult stem cells (SC). Adult stem cells are the only cells
that persist in the tissue for a suﬃcient length of time
to acquire the requisite number of genetic changes for
neoplastic development. In contrast to intestinal mucosa
and epidermis where a steady ﬂux of cells occurs from the
stem cell zone to the terminally diﬀerentiated cells that are
imminently to be lost, liver normally exhibits a very low
level of cell turnover. However, when abnormal hepatocyte
loss occurs, such as after partial hepatectomy (PH) or toxic
injury, the liver demonstrates an enormous regenerative
capacity. The clonality of HCC is now well established based
upon the studies examining viral integration sites of HBV
in tumor samples [5], as well as on the determination
of restriction fragment length polymorphisms of X-linked
g e n e si nt u m o rc e l l s[ 6]. However, the cell type that has given
rise to HCC has not been universally accepted. From the
models of experimental hepatocarcinogenesis, there may be
at least three distinct cell lineages with progenitor properties
susceptible to neoplastic transformation [7].
2. The Stem Cell Origin of Liver Cancer
2.1. Hepatocytes Have “Stem Cell” Properties. Hepatocytes in
normal adult liver have a lifespan of over a year. However,
in response to parenchymal cell loss, the hepatocytes restore
the liver mass by self-replication. In rodents, the liver
can restore its original volume after two-thirds partial
hepatectomy (PH) in approximately 10 days [8, 9]. Serial
transplantation experiments have shown that hepatocyte
can divide at least 69 times, demonstrating the clonogenic
potential of hepatocytes—one of the crucial properties of an
SC [10]. In HCV infected liver, the hepatocyte proliferation2 International Journal of Hepatology
rate increases with increasing cellular damage [11]. Many
models of liver cancer utilize a brief exposure to a genotoxic
carcinogen at a time when the liver is in a proliferative
state, either during the period after a PH or necrogenic
insult [12]. Hepatocytes have been found to be directly
involved in carcinogenesis of HCC in 2-acetylaminﬂourene
and DEN-treated rats where hepatocytes were labeled with
β-galactosidase [13]. Hepatocytes in proliferation appear to
be the origin of cancer.
2.2. Oval/Liver Progenitor Cells as Targets for Malignant
Transformation. Whenhepatocyteand/orcholangiocytesare
damaged or inhibited in their proliferation, a potential
SC compartment located within the smallest branches of
the intrahepatic biliary tree, the ductules, and canals of
Hering gets activated [14]. The “oval cells” in rodent or “the
liver progenitor cells” in human liver involve a population
of cells that are bipotential and capable of diﬀerentiating
into hepatocytes or cholangiocytes. The oval/progenitor cells
are labeled by over 30 surface markers including biliary-
type cytokeratin (CK), CK7, CK19, oval cell markers OV6
and OV1, neuroendocrine marker chromogranin A, neural
cell adhesion molecule and parathyroid hormone-related
peptide, and connexin 43. The origin of HCC from hepatic
progenitor cells (HPC) is is often suggested from the fact
that tumors contain an admixture of mature cells and
cells phenotypically similar to HPCs [15, 16]. Oval/HPC
proliferations and activations are observed after severe liver
parenchyma injury, viral hepatitis, alcoholic hepatitis, and
nonalcoholic fatty liver disease. HPC/oval cell activation
accompanies many instances of liver damage, irrespective of
etiology, suggesting such cells are carcinogen targets during
hepatocarcinogenesis. Oval cells from p53-null mice formed
HCC when transplanted into athymic nude mice [17]. A
probable origin from oval cells is suggested by the fact that
if oval cell expansion is blocked in the CDE diet mouse
modelingbytargetingc-Kitwithimatinibmesylate,theHCC
formation is reduced [18]. Furthermore, the gene expression
proﬁle from a selected group of HCC is consistent with the
proﬁle of HPCs.
2.3. Bone Marrow-Derived Stem Cells. Petersen et al. demon-
strated that hepatocytes could be derived from circulating
bone marrow cells [19]. Hematopoietic Stem Cells (HSC)
from wild-type mice were able to repopulate the liver of
FAH-deﬁcient (fah−/−)m i c e[ 20]. In the setting of sex-
mismatched bone marrow transplantation, bone marrow-
derived hepatocyte are found in the recipient liver with a
large variation in their frequency ranging from less than
1% to >40%. However, in a chimerical mouse model with
genetically labeled bone marrow, there was no malignant
transformation of the bone marrow-derived liver SC during
hepatocarcinogenesis induced by chemical carcinogen [20].
These results suggest that bone marrow-derived liver SC may
not be targets for malignant transformation in HCC.
2.4. Isolation of Liver Cancer Stem Cells. In the last decade,
identiﬁcation of speciﬁc cell surface markers for each of
the liver cell type, production of corresponding monoclonal
antibodies, and cell sorting techniques have together rev-
olutionized the characteristics of normal stem cells. It has
been show that cancer SCs in HCC can be identiﬁed by
several cell surface antigen CD133, CD90, CD44, OV6, and
epithelial cell adhesive molecule (EpCAM), or by selecting
the side population (SP) cells in Hoechst dye-staining [21–
25]. Table 1 shows markers that are associated with liver
cancer SC. The surface markers enrich HCC cells with
greater tumorigenicity in immunodeﬁcient mice, higher
colon-forming eﬃciency, and proliferation ability in vitro. In
addition, most of the markers are found to be expressed in
only a minute proportion of HCC cells, and the expression
of the markers correlate with poor prognosis and tumor
recurrence.However,itremainstobeseenhowmuchoverlap
there is between these various markers, or whether there
is a “one-ﬁts-all” marker for cancer SCs in HCC. Most of
the markers which are used for isolating cancer SCs from
primary tumor samples were established and adapted from
established cancer cell lines. It is not clear whether the cancer
SCs that are derived from established cancer cell lines and
cultured in vitro reﬂect the SCs from primary tumor in
the gene expression of these surface marker. It remains a
challenge to isolate enough clonally derived cancer SCs from
primary tumor without in vitro propagation for lineage
tracking and diﬀerentiation experiments, identiﬁcation of
deregulated signaling pathways that lead to the malignant
transformation of normal adult SC to cancer SCs.
2.5. Pathways Important for Stem Cell Function Are Deregu-
lated in Hepatocarcinogenesis. From HCC animal model and
gene array analysis, a growing body of research suggests that
many signaling pathways known to be involved in SC main-
tenance, self-renewal, and pluripotency, are altered in HCC.
This alteration may result in the malignant transformation
of liver SC [26]. These observations support the hypothesis
that molecular changes in HCC originate in cancer SC [27].
Moreover, these pathways could serve as prognostic markers
and targets for therapeutic interventions [27].
3. WNT/β-Catenin
Disrupted Wnt signaling is observed in approximately one-
third of all HCC which underscores its importance in car-
cinogenesis [28]. The Wnt pathway has a fundamental role
in embryogenesis with signaling eﬀects on proliferation and
apoptosis in developing cells [29]. Wnt pathway activation is
essential for maintenance of SC compartment and regulates
cellular diﬀerentiation [30]. The “canonical Wnt pathway”
describes a cascade of events beginning with the translo-
cation of β-catenin from the cell membrane into nucleus,
where β-catenin then acts as a coactivator of the TCF/LEF
family of transcription factors, these in turn regulate speciﬁc
target genes including c-myc, cyclin D1, and survivin [31].
The signaling cascade is normally initiated when Wnt ligand
binds to Frizzled (FZD), a transmembrane receptor [32].
FZD then signals to β-catenin to escape its association with
E-cadherin. The cytoplasmic elements of the activated Wnt
pathway prevent β-catenin from being phosphorylated by aInternational Journal of Hepatology 3
Table 1: Markers that have aided in the identiﬁcation of stem cells.
Markers
Cluster of diﬀerentiation (CD)133+
CD44+
CD45−
CD90+
CD34
OV6
Side population (SP)
Epithelial cell adhesion molecule (EpCAM)
OC.2, OC.3, OC.4, OC.5, OC.10
BDS7
Thy-1
c-kit
ABCG2/BCRP1(breast cancer resistance protein)
Connexin 43
Tumor rejection antigen 1-81 (TRA-1-81)
TRA-1-60
Sry-box containing gene 2 (SOX2)
Surface antigen stage-speciﬁc embryonic antigen 3 (SSEA-3)
CK7, CK19, CK14
α-fetoprotein (AFP)
γ-glutamyltranspeptidase
Placental form of glutathione-S-transferase
Flt-3 ligand
DMBT1(deleted in malignant brain tumor 1)
Neural cell adhesion molecule 1(NCAM)/CD56
Chromogranin A
Parathyroid hormone related peptide (PTHrP)
degradation complex made up of a serine-threonine kinase,
GSK3B,proteinscaﬀolds,AXIN,andadenomatouspolyposis
coli (APC) [29, 31, 32]. Mutations of proteins that may
allow β-catenin accumulation in the nucleus to promote
transcription of its target genes are found in many cancers
[33]. Mutation of β-catenin, described in HCC, is located in
exon 3 of the CTNNB1 gene, which is the phosphorylation
site for GSK3B, AXIN1, and AXIN2 mutation. Activation
of Wnt signaling has also been demonstrated in diﬀerent
prospectively isolated SC [34]. 20 to 40% of human HCC
bear abnormal cytoplasmic and nuclear accumulation of β-
catenin by immunohistochemical staining [35]. Markers for
elevating expression of Wnt include CD 133+ and EpCAM+
[36]. The knockdown of the expression of EpCAM, a
Wnt/beta-catenin signaling target, in liver cancer SC resulted
in decreased proliferation, colony formation, migration, and
drug resistance [36]. RNA interference machinery- (RNAi-)
mediated knockdown of β-catenin resulted in the inhibition
of lung cancer SCs [34].
4. Transformation Growth Factor-Beta (TGF-β)
A wide range of secreted factors regulate SC proliferation
and fate. TGF-β shows remarkable functional conservation
between species and between tissues that self-renew through
asymmetricdivisionsorpopulationalasymmetry.TGF-βsig-
naling is important for embryonic hepatocyte proliferation,
as well as in the formation of gastrointestinal cancer [37–
39]. Tang et al. demonstrated that lack of responsiveness
to TGF-β pathway in liver SC led to carcinogenesis [40].
Subsequently, it has been shown that targeting this pathway
using indirect modulation of IL6/STAT3 appeared to be
eﬀective in eradication of cancer SC [26, 40].
5.Hedgehog
The Hedgehog signaling pathway consists of a complex suite
ofmoleculeswhichregulatecelldiﬀerentiation,regeneration,
and stem cell biology. The pathway plays important roles
in the development and homeostasis of the gut tissue [41].
Studies have identiﬁed a possible role for this pathway in
HCC with expression of Sonic, the predominant ligand of
the Hedgehog pathway in liver, that is present in up to 60%
of human HCC samples [42, 43]. The Hedgehog pathway is
deregulated in hepatocarcinogenesis [42]. Genes involved in
the Hedgehog pathway are highly expressed in tumorigenic
CD133+ liver cancer SC [21]. Suppression of Hedgehog
pathway not only decreased HCC cell proliferation but also
chemosensitized HCC cells to 5-ﬂuorouracil and to the
induction of cell apoptosis [44].
6. Target CSCsinthe Treatmentof HCC
Cancer SCs are predicted to mediate tumor recurrence after
chemo- and radiation-therapy due to the relative inability of
these modalities to eﬀectively target cancer SCs. Eradicating
Cancer SCs brings the hope for cure. Interesting results
have been demonstrated in inhibiting breast cancer SC
by targeting TGF-β and Notch pathways [45]. Similarities
between normal and malignant SC, at the levels of cell-
surface proteins, molecular pathways, cell cycle quiescence,
and microRNA signaling present challenges in developing
cancer SC-speciﬁc therapeutics. Treatment against cancer
SCs should be developed targeting known stem cell regula-
tory pathways that are deregulated in cancer SCs compared
to normal SC, as well as through unbiased high-throughput
siRNA or small molecule screening. Both experimental
approaches require identiﬁcation and characterization of the
putative liver cancer SC in order to target liver cancer SC
speciﬁcally to decrease the toxicities. The current strategies
of identifying cancer SCs are based on the expression of
extracellular markers, the growth of cancer SCs in tumor
sphereassaysundernondiﬀerentiatingconditions,dyeexclu-
sion due to the overexpression of drug eﬄux pumps in
cancer SCs, and greater tumorigenicity in immunodeﬁcient
mice compared cancer cells that are not cancer stem cells.
Despite the amount of literature on liver cancer SCs, it is still
not clear as to what constitutes a universal liver cancer SC-
speciﬁc proﬁle. Given the fact that the diverse etiology for
hepatocarcinogenesis and multiple types of progenitor cells
are involved in malignant transformation, it is unlikely that
a universal liver cancer SC-speciﬁc proﬁle will be used for
therapeutics development. Ultimately, targeting liver cancer4 International Journal of Hepatology
SCs in treating HCC will be in the context of personalized
medicine.
7. Concluding Remark
Current research supports that HCC derived from malignant
transformation of HPC. There may be at least three distinct
cell lineages with progenitor cell properties susceptible to
neoplastic transformation: hepatocyte, oval/hepatic progen-
itor cells, and bone marrow-derived stem cells. Multiple
signaling transduction pathways important for stem cell
proliferation and diﬀerentiations are found deregulated
during hepatocarcinogenesis. Strategies are being developed
to identify and characterize the liver cancer SCs. Targeting
liver cancer SCs may bring hope in curing HCC.
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